A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Inclusion Criteria
Exclusion Criteria
Clinical.Trials@bms.com855-907-3286
Belo Horizonte, Minas Gerais 30150-221, Brazil
Curitiba, ParanĂ¡ 80250-060, Brazil
Plovdiv, 4002, Bulgaria
Chongqing, Chongqing Municipality 400065, China
Hangzhou, Zhejiang 310057, China
Istanbul- Fatih, Istanbul 34098, Turkey (TĂ¼rkiye)
+905322129111
+558532240552
+5531984545405
4133101356
+5581999983400
5551999897478
11974912009
11996588290
+359876324578
13012352441
+8613160897678
111111
13500889222
13685773988
862164931122
+420602668887
420727812317
091318533118
00494020923698
00393272022085
+393297973141
+40723400453
0040722557297
667517630
+34913368571
+34961244792
+905327629003